The E2A program develops structured, continuously updated tools and frameworks that evaluate alignment between pharmaceutical asset profiles and anticipated HTA environments at projected launch dates.
View Program Details Express InterestPharmaceutical development teams are increasingly exposed to uncertainty about how future health technology assessment bodies will judge new therapies. Methods are shifting, evidentiary expectations are tightening, and new working groups are signalling changes that will reshape how value is interpreted at the time most early assets reach the market.
HTA evaluation approaches changing rapidly
Higher evidentiary expectations
More therapies entering pipelines
Shrinking innovation funding
The program develops in two stages. Stage one builds the trained LLM and knowledge base through expert elicitation and collaborative framework development. Stage two operationalizes the framework, enabling participating organizations to generate value binding scores with domain-level commentary for their early-stage assets.
The program invites HTA methodologists, assessment body representatives, and pharmaceutical development leaders to participate in framework development.
Express Interest in Participation